Key result
COVID-19-associated myocardial injury and myocarditis are linked to poor prognosis and mortality.
Why the study?
COVID-19-associated myocardial injury is linked to poor prognosis and mortality, emphasizing the need for effective monitoring and management strategies.
This narrative review summarizes the clinical evidence, pathogenesis, diagnostic tools, and therapeutic strategies for managing COVID-19-associated myocardial injury and myocarditis.
After its initial outbreak in 2019, the 2019 novel coronavirus disease (COVID-19) remains a global health concern. COVID-19 is well known for causing severe respiratory pathology, but it can also cause a variety of extra-pulmonary manifestations. Among them, myocardial injury has received substantial attention because it is usually associated with poor prognosis and mortality, thus emphasizing the importance of monitoring and managing myocardial injury in patients with COVID-19. Myocarditis has received attention as a complication of myocardial injury during and after the onset of COVID-19. Here, to aid in clinical decision-making, we present a narrative review on COVID-19- associated myocardial injury and myocarditis, discussing clinical evidence, pathogenesis, diagnostic tools, and therapeutic strategies.
No takes yet. Share an insight, caveat, or question.
Xiang et al. (2023) conducted a review in COVID-19-associated myocardial injury and myocarditis. COVID-19-associated myocardial injury and myocarditis are significant complications linked to poor prognosis and mortality, requiring careful monitoring and management.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: